8-K: STRATA Skin Sciences Amends Credit Agreement, Secures Waiver for Revenue Covenant Breach

STRATA Skin Sciences has amended its credit agreement with MidCap Financial Trust, obtaining a waiver for a prior revenue covenant breach and adjusting future financial targets.

Summary

• STRATA Skin Sciences has entered into Amendment No. 4 to its Credit and Security Agreement with MidCap Financial Trust and other lenders.
• This amendment includes a limited waiver for a previous default related to not meeting the minimum net revenue threshold for the period ending December 31, 2023.
• The agreement also revises the minimum net revenue financial covenant for future periods.
• The new minimum net revenue targets are set at $29.0 million, $29.25 million, $29.5 million, and $30.0 million for the periods ending March 31, 2024, June 30, 2024, September 30, 2024, and December 31, 2024, respectively.
• A second amended and restated fee letter was also agreed upon, outlining various fees payable to MidCap, including an origination fee of $40,000 paid on September 30, 2021.
• The agreement includes an exit fee of 4% of the total principal amount of credit extensions, less any partial exit fees previously paid.
• Origination fees of 0.50% were also paid on Credit Facility #2 and will be paid on Credit Facility #3.

Sentiment

Score: 5

Explanation: The document indicates a necessary but not entirely positive situation. While the company secured a waiver and revised targets, it also highlights a previous failure to meet financial obligations. The sentiment is neutral to slightly negative due to the need for a waiver.

Positives

• The company successfully obtained a waiver for a prior default, avoiding potential enforcement actions by lenders.
• The revised minimum net revenue targets provide more realistic and achievable goals for the company.
• The amendment allows the company to continue accessing credit facilities under the agreement.

Negatives

• The company failed to meet its minimum net revenue target for the period ending December 31, 2023, leading to a breach of the financial covenant.
• The company is required to pay various fees, including origination and exit fees, which increase the overall cost of borrowing.

Risks

• The company must meet the revised minimum net revenue targets to avoid future defaults.
• The exit fee of 4% could be a significant expense upon full repayment of the loan.
• The company's financial performance is still subject to market conditions and other factors that could impact its ability to meet its obligations.

Future Outlook

The company must meet the revised minimum net revenue targets to avoid future defaults and ensure continued access to credit facilities. The agreement also sets a minimum net revenue amount for periods after December 31, 2026, to be determined by the Agent in consultation with the Borrower.

Industry Context

This amendment reflects the challenges faced by companies in meeting financial covenants, particularly in dynamic market conditions. It is not uncommon for companies to renegotiate terms with lenders to ensure continued access to capital.

Comparison to Industry Standards

• Restructuring debt agreements and amending financial covenants are common practices in the current economic environment, especially for companies with fluctuating revenue streams.
• The specific terms of the agreement, such as the 4% exit fee, are within the range of what is seen in similar credit agreements, but the exact percentage can vary based on the risk profile of the borrower and the lender's appetite.
• Companies like Cutera and Cynosure, which also operate in the medical aesthetics space, have also had to manage their debt and financial covenants, although the specific terms of their agreements may differ.

Stakeholder Impact

• Shareholders may be concerned about the company's failure to meet its previous financial targets.
• Lenders have agreed to a waiver and revised terms, indicating a willingness to work with the company.
• Employees may be indirectly affected by the company's financial performance and ability to meet its obligations.

Next Steps

• The company must meet the revised minimum net revenue targets for the upcoming quarters.
• The company will need to pay the origination fee for Credit Facility #3 upon funding.
• The company will need to manage its debt obligations and ensure compliance with the amended credit agreement.

Key Dates

Keywords

credit agreement, loan, waiver, net revenue, financial covenant, MidCap Financial, origination fee, exit fee, lenders, STRATA Skin Sciences